Abstract: Objective To investigate the effect of imrecoxib combined with Zhengqing Fengtongning Sustained Release Tablets in the treatment of patients with rheumatoid arthritis. Methods A total of 97 patients with rheumatoid arthritis were randomly divided into experimental group(n=50)and control group(n=47). Patients in the experimental group were treated with imrecoxib and Zhengqing Fengtongning Sustained Release Tablets, while patients in the control group were treated with imrecoxib. Levels of erythrocyte sedimentation rate(ESR), C reactive protein(CRP), rheumatoid factor(RF), the number of swelling joints, Visual Analogue Scale(VAS)score of pain, the total effective rate and total apparent efficiency rate were compared between the two groups before and after treatment. Results After treatment, the ESR, CRP and rheumatoid factor levels of the both groups were significantly lower than those before treatment, and the ESR level of the experimental group was significantly lower than that of the control group(P<0.05). After treatment, the number of swelling joint showed significant difference between the two groups(P<0.05). There was a significant difference in the total effective rate between the two groups(P<0.05). There was no significant difference in total apparent efficiency rate between the two groups(P>0.05). Conclusion Imrecoxib combined with Zhengqing Fengtongning Sustained Release Tablets can effectively reduce the level of inflammatory factors and improve the efficiency of treatment in patients with rheumatoid arthritis.